A Promising Drug Target: RPL18P1 (RPL18_7_1361) (G326291)

Target Name: RPL18P1

NCBI ID: G326291

RPL18P1

Other Name(s): RPL18_7_1361 | Ribosomal protein L18 pseudogene 1 | ribosomal protein L18 pseudogene 1

A Promising Drug Target: RPL18P1 (RPL18_7_1361)

RPL18P1 (RPL18_7_1361), a gene encoding a protein known as protamine phosphate synthase (PMS), is a promising drug target and a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The identification of RPL18P1 as a potential drug target has generated a significant amount of interest in the scientific community due to its unique mechanism of action and its potential to modulate cellular processes involved in disease progression.

Molecular Mechanism

RPL18P1 is a member of the RPL18 family, which is known for its role in the synthesis of RNA using the amino acid uracil instead of the more common amino acid guanine. RPL18P1 is responsible for the synthesis of protamine phosphate (PMP), which is a crucial cofactor for the enzyme poly (A) polymerase (PAP), which is involved in the regulation of gene expression and cell growth.

PMP plays a vital role in various cellular processes, including DNA replication, transcription, and translation of RNA. PMP has been linked to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The levels of PMP in cancer cells are often elevated, and studies have shown that inhibiting PMP synthesis or activity can be an effective strategy for cancer treatment.

Drug Interaction with RPL18P1

RPL18P1 is a drug target of great interest due to its unique mechanism of action and its potential to modulate cellular processes involved in disease progression. Several studies have investigated the effects of drugs on RPL18P1 expression and its function in various cellular processes.

One of the most promising drug targets associated with RPL18P1 is the inhibitor, MK-8628, which is a small molecule that inhibits the activity of RPL18P1. Studies have shown that MK-8628 can significantly reduce the levels of PMP in cancer cells, leading to a decrease in cell proliferation and a suppression of cancer cell growth.

Another drug that has been shown to interact with RPL18P1 is the drug erlotinib, which is a small molecule inhibitor of the PI3K/Akt signaling pathway. erlotinib has been shown to inhibit the activity of RPL18P1, which results in a decrease in the levels of PMP in cancer cells.

Targeting RPL18P1

The identification of RPL18P1 as a potential drug target has generated a significant amount of interest in the scientific community due to its unique mechanism of action and its potential to modulate cellular processes involved in disease progression. To effectively target RPL18P1, scientists have developed several compounds, including MK-8628 and erlotinib, which can inhibit the activity of RPL18P1.

Conclusion

RPL18P1 is a promising drug target and a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The identification of RPL18P1 as a potential drug target has generated a significant amount of interest in the scientific community due to its unique mechanism of action and its potential to modulate cellular processes involved in disease progression. Further research is needed to fully understand the effects of drugs on RPL18P1 expression and its function in various cellular processes.

Protein Name: Ribosomal Protein L18 Pseudogene 1

The "RPL18P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL18P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets